Trials / Completed
CompletedNCT06347887
Clinical Validation of ColonAiQ (a Blood-based Assay Targeting ctDNA Methylation) for Colorectal Cancer Detection
Clinical Validation of ColonAiQ (a Blood-based Assay Targeting Circulating Tumor DNA Methylation) for Colorectal Cancer Detection
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,965 (actual)
- Sponsor
- Singlera Genomics Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The DNA methylation targets in preoperative plasma samples of the subjects will be detected by the multi-gene methylation test (ColonAiQ), and the test accuracy will be evaluated by compared with the clinical diagnosis evidence.
Detailed description
The accuracy of ColonAiQ test in clinical testing will be evaluated in the multicenter, prospective study. Patients with colorectal cancer, intestinal polyps, adenomas and other non-neoplastic diseases of the digestive system, and patients with non-colorectal cancer such as gastric cancer, esophageal cancer, breast cancer and lung cancer will be enrolled. In this study, all cfDNA will be tested by fluorescence quantitative PCR, and some samples will be tested by NGS to verify the effectiveness of ColonAiQ test. Clinical diagnosis reports and methylation test results will be blinded to the lab tester and clinician respectively.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | ColonAiQ test and Colonoscopy | Diagnostic Test |
Timeline
- Start date
- 2021-05-31
- Primary completion
- 2024-01-16
- Completion
- 2024-01-16
- First posted
- 2024-04-04
- Last updated
- 2024-06-03
Locations
7 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06347887. Inclusion in this directory is not an endorsement.